Mikrobiyotanın Kanser Tedavilerindeki Rolü

Łukasiewicz K, Fol M. Microorganisms in the treatment of cancer: advantages and limitations. J Immunol Res, 2018;2018: 2397808. doi: 10.1155/2018/2397808.

Fernandes MR, Aggarwal P, Costa RGF, et al. Targeting the gut microbiota for cancer therapy. Nat Rev Cancer, 2022;22(12): 703-722. doi: 10.1038/s41568-022-00513-x.

Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD1 efficacy. Science, 2015;350(6264): 1084-1089. doi: 10.1126/science.aac4255.

Lida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science, 2013;342(6161): 967-970. doi: 10.1126/science.1240527.

Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 2015;350(6264): 1079–1084. doi: 10.1126/science.aad1329.

Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science, 2013; 342(6161): 971–976. doi: 10.1126/science.1240537.

Spanogiannopoulos P, Bess EN, Carmody RN, et al. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol, 2016;14(5): 273-287. doi: 10.1038/nrmicro.2016.17.

Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer, 2017;17(5): 271-285. doi: 10.1038/nrc.2017.13.

Fujita K, Sparreboom A. Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr Clin Pharmacol, 2010;5(3): 209-217. doi: 10.2174/157488410791498806.

Stringer AM, Gibson RJ, Logan RM, et al. Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther, 2008;7(12): 1919-1925. doi: 10.4161/cbt.7.12.6940.

Wallace BD, Wang H, Lane KT, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science, 2010;330(6005): 831-835. doi: 10.1126/science.1191175.

Galluzzi L, Buqué A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell, 2015;28(6): 690-714. doi: 10.1016/j.ccell.2015.10.012.

Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer, 2007;7(8): 573-584. doi: 10.1038/nrc2167.

Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol, 2011;18(1): 18-25. doi: 10.3747/co.v18i1.708.

Bracci L, Moschella F, Sestili P, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res, 2007;13(2 Pt 1): 644-653. doi: 10.1158/1078-0432.CCR-06-1209.

Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol, 2004;34(2): 336-344. doi: 10.1002/eji.200324181.

Schiavoni G, Sistigu A, Valentini M, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res, 2011;71(3): 768-778. doi: 10.1158/0008-5472.CAN-10-2788.

Daillère R, Vétizou M, Waldschmitt N, et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity, 2016;45(4): 931-943. doi: 10.1016/j.immuni.2016.09.009.

Uribe-Herranz M, Rafail S, Beghi S, et al. Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response. J Clin Invest, 2020;130(1): 466-479. doi: 10.1172/JCI124332.

Shiao SL, Kershaw KM, Limon JJ, et al. Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy. Cancer Cell, 2021;39(9): 1202-1213.e6. doi: 10.1016/j.ccell.2021.07.002.

Crawford PA, Gordon JI. Microbial regulation of intestinal radiosensitivity. Proc Natl Acad Sci USA, 2005;102(37): 13254-13259. doi: 10.1073/pnas.0504830102.

Grootaert C, Van de Wiele T, Van Roosbroeck I, et al. Bacterial monocultures, propionate, butyrate and H2O2 modulate the expression, secretion and structure of the fasting-induced adipose factor in gut epithelial cell lines. Environ Microbiol, 2011;13(7): 1778-1789. doi: 10.1111/j.1462-2920.2011.02482.x.

Guo H, Chou WC, Lai Y, et al. Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites. Science, 2020;370(6516): eaay9097. doi: 10.1126/science.aay9097.

Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science, 2013;342(6165): 1432-1433. doi: 10.1126/science.342.6165.1432.

Peggs KS, Quezada SA, Korman AJ, et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol, 2006;18(2): 206-213. doi: 10.1016/j.coi.2006.01.011.

Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature, 2011;480(7378): 480-489. doi: 10.1038/nature10673. PMID: 22193102;

Chang R, Shirai K. Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. BMJ Case Rep, 2016;2016: bcr2016216426. doi: 10.1136/bcr-2016-216426.

Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer, 2010;116(7): 1767-1775. doi: 10.1002/cncr.24951.

Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature, 2001;411(6835): 380-384. doi: 10.1038/35077246.

Paulos CM, Kaiser A, Wrzesinski C, et al. Toll-like receptors in tumor immunotherapy. Clin Cancer Res, 2007;13(18 Pt 1): 5280-5289. doi: 10.1158/1078-0432.CCR-07-1378.

Paulos CM, Wrzesinski C, Kaiser A, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest, 2007;117(8): 2197-2204. doi: 10.1172/JCI32205.

Bowers JS, Nelson MH, Kundimi S, et al. Dendritic cells in irradiated mice trigger the functional plasticity and antitumor activity of adoptively transferred Tc17 cells via IL12 signaling. Clin Cancer Res, 2015;21(11): 2546-2557. doi: 10.1158/1078-0432.CCR-14-2294.

Shigematsu A, Adachi Y, Koike-Kiriyama N, et al. Effects of low-dose irradiation on enhancement of immunity by dendritic cells. J Radiat Res, 2007;48(1): 51-55. doi: 10.1269/jrr.06048.

Awedan AA. High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma. Ann Transplant, 2002;7(2): 38-43.